
Core Scientific reports another 48 MW delivered at Dalton campus
The July presentation showed about 30 MW billing against 175 MW leased at Dalton; the new update leaves acceptance and revenue timing unspecified.

Expansion Zone drilling targets growth beyond the preliminary mine plan; only part of the exploration results is expected to enter the feasibility study.

The July presentation showed about 30 MW billing against 175 MW leased at Dalton; the new update leaves acceptance and revenue timing unspecified.

The province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.
The Ontario infill interval has an estimated true width of 75.7 metres, while the hole ended in mineralization beyond the current pit limit.
Intel, Micron and Sandisk advanced, while Micron's latest quarterly results showed higher cloud-memory and data-centre revenue.

The 1,223 BTC purchase takes holdings to 36,818, while warrant exercises and a pending preferred offering reshape the capital base.

The completed acquisition uses US$95 million in cash and US$21 million in equity, adding four manufacturing facilities and about 400 employees.

The infill assays will inform an updated resource and feasibility study for the Premier mill restart in British Columbia.

The provisional funding would support research components and regular progress reports; the company gave no final approval date.
The 183-patient APOLLO study met both primary endpoints, with an FDA resubmission planned by the end of 2026.
An unnamed customer is due to deploy 3 MW on Nov. 1, with initial monthly bills split between US$750,000 in service fees and power charges.
The electrolyser maker ended April with £215.6 million in cash, supported by a £40 million equity investment from Great British Energy.
The mine produced 39 ounces in September and forecasts about 500 ounces in December as equipment and processing changes take effect.
The AI infrastructure developer says financing and an investment disposal supported its cash increase as first-half revenue fell sharply.
Loughton was due to host about 23,000 chips from early 2027, while Nscale is pursuing an IPO after announcing convertible financing.
Pure holdings remained at zero in the Oct. 16 snapshot, but the weekly post disclosed neither sale prices nor dollar proceeds.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Selected Calandrias feed lifted mill production as Cerrado targeted the upper end of its unchanged annual guidance range.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The Vanderbilt development partnership will pair CT imaging with blood biomarkers, with initial performance data due Dec. 3.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.
Coin-cell testing supports a move to larger pouch prototypes, while government and defence procurement qualification remains a longer-term goal.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The Oct. 15 petition asks to participate in the PUC case over transmission costs and interruptible service for large data centres.

The revision incorporates Vogtle construction experience, with a Dec. 28 effective date conditional on the NRC comment process.

Langer Heinrich produced 1.00 million pounds in the September quarter, while unit production costs rose to US$61.6 a pound.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Cash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.

The Oct. 15 move leaves Curaleaf's national store count at 189, with a York grand opening celebration scheduled for Oct. 23.

Three brands will be dropped as global teams take over operations, with full annualized savings forecast for fiscal 2028.

The approval adds adults with high-grade, BCG-unresponsive disease ahead of the Jan. 6, 2027 review target.